Tarsus Pharma Q3 revenue beats estimates, driven by XDEMVY sales

Tarsus Pharmaceuticals

04/11/2025 21:59

Overview

Tarsus Q3 revenue of $118.7 mln beats analyst expectations, driven by XDEMVY sales

Net loss for Q3 narrows to $12.6 mln from $23.4 mln in 2024

Company sees 30% increase in weekly multi-patient prescribers in Q3

Outlook

Company plans Phase 2 study for TP-04 in December 2025

Company expects topline data for TP-04 by year-end 2026

Company plans Phase 2 study for TP-05 in 2026

Result Drivers

XDEMVY SALES GROWTH - XDEMVY net sales increased 147% year-over-year, reaching $119 mln, reflecting strong commercial momentum

INCREASED PRESCRIBERS - 30% increase in weekly multi-patient prescribers in Q3, indicating strong integration into clinical practice

BROAD COVERAGE - Over 90% coverage across commercial, Medicare, and Medicaid lives, supporting sales growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$118.69 mln
$113.10 mln (6 Analysts)
Q3 EPS
-$0.30
Q3 Net Income
-$12.58 mln
Q3 Basic EPS
-$0.30


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is $85.00, about 17.9% above its November 3 closing price of $69.79

The stock recently traded at 85 times the next 12-month earnings vs. a P/E of 121 three months ago

Press Release: ID:nGNX51gSZ6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)